Evidence map›Paper›PMID 42519171›Full record

ReviewBlood neoplasia2026

Menin inhibitors as a treatment for acute leukemia: from bench to the clinic.

Justin Watts, Ellen Madarang, Tomasz Cierpicki, Jolanta Grembecka

Abstract readReview
In one paragraph

Review in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Justin WattsDepartment of Medicine, University of Miami, Miami, FL.
Ellen MadarangDepartment of Medicine, University of Miami, Miami, FL.
Tomasz CierpickiDepartment of Pathology, University of Michigan, Ann Arbor, MI.
Jolanta GrembeckaDepartment of Pathology, University of Michigan, Ann Arbor, MI.

Funding

Development of ASH1L inhibitors for acute leukemiaR01CA244254 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GREMBECKA, JOLANTA · 2020 to 2024
$2.8M
Targeting Menin in Acute Leukemia with Upregulated HOX GenesR01CA272561 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jolanta Grembecka · 2023 to 2026
$2.5M
Targeting PRC1 in leukemiaR01CA282082 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Tomasz Cierpicki · 2023 to 2026
$2.5M
Overcoming resistance to menin patient mutations in leukemiaR01CA303099 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jolanta Grembecka · 2025 to 2026
$1.3M
NCI NIH HHS R01 CA244254NCI NIH HHS R01 CA272561NCI NIH HHS R01 CA282082NCI NIH HHS R01 CA303099
6 · The paper itself

Abstract

Menin inhibitors exploit the key biological mechanism behind

Identifiers

PMID42519171
PMCPMC13382185

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.